An observational study in Wilson's Disease, sponsored by Wan-Jin Chen. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2019-09-23.
Sponsored by Wan-Jin Chen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Hepatolenticular Degeneration with a site in China — 10 open to participants now, 11 under way, 1 of them phase 3. Hepatolenticular Degeneration · China.
Among the 15 studies in Hepatolenticular Degeneration with a site in China, this one is one of 2 that started in 2019, is one of 6 observational ones, reaches primary completion later than 10 of the 10 other live ones, and was the 4th registered.
80 studies on the registry are indexed under Hepatolenticular Degeneration; 31 are open to participants now.
Browse Hepatolenticular Degeneration studies →10 of the 15 studies in Hepatolenticular Degeneration with a site in China are open now. Recruiting first, the newest first:
Orphalan · Sites in China, United States, Pakistan and 1 more country
Ages 8+
GeneCradle Inc · Sites in China
Ages 18+
DSciLab Co., Ltd. · Sites in China
Ages 18+
Chaohui Yu · Sites in China
Ages 10–60
Jun Li · Sites in China
Ages 15–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 22 Hepatolenticular Degeneration studies recruiting now, 17 (77%) set no upper age limit and 4 (18%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 2 · Phase 3 1 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 72 across 35 observational studies indexed under Hepatolenticular Degeneration.
Median enrollment 18 across the 9 interventional studies, 600 across the 6 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 15 have an industry lead sponsor. The 10 most frequent:
Wan-Jin Chen is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Wan-Jin Chen has 1 study filed under Hepatolenticular Degeneration — fewer than ten, so there is no comparison to draw.
1 of the studies in Hepatolenticular Degeneration with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06650319Chaohui YuA Clinical Study to Evaluate the Safety and Efficacy of LY-M003 Injection in Patients With Wilson Disease | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Hepatolenticular Degeneration with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to determine the clinical spectrum and natural progression of Wilson's Disease in a prospective multicenter natural history study, to assess the clinical, genetic, epigenetic features and biomarkers of patients with Wilson's Disease to optimize clinical management.
Patients with Wilson's Disease are diagnosed by the clinical and/or genetic features
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
* Participants are unable to comply with study procedures and visit schedule
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: No intervention
Other: No intervention
Other: No intervention
Other: No intervention
No intervention
The change of Unified Wilson's Disease Rating Scale (UWDRS)
Disease severity will be assessed by application of the Unified Wilson's Disease Rating Scale (UWDRS), a clinical rating scale consists of three subscales. Higher UWDRS total scores indicate more severe disease.
Time frame: Up to 30years
Started Jul 2019 (actual). Primary completion is estimated for Dec 2039, 245 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hepatolenticular Degeneration →
Wan-Jin Chen